Source claims OPEC and non-OPEC states finalizing results of meeting, agreement 'close'Business & Economy December 10, 17:07
Bloomberg: Non-OPEC states agree to cut oil production by more than 600,000 barrelsBusiness & Economy December 10, 16:22
More than 20 states that produce more than half of world's oil take part in OPEC meetingBusiness & Economy December 10, 13:05
Russian energy minister Novak sees 'no risk' OPEC agreement failsBusiness & Economy December 10, 12:43
Defense ministry organizes mass escape for Aleppo civilians via humanitarian corridorsWorld December 10, 12:38
Almost 18,000 civilians evacuated from areas of Aleppo controlled by militantsWorld December 10, 7:41
Russian swimmers win 11 sets of medals at FINA World Swimming Championships (25 m)Sport December 10, 7:00
Shiveluch volcano in Russia’s Far East spews ash to 11 km in airWorld December 10, 5:28
Ceasefire agreements enter into force near Damascus, in Idlib province ― mediaWorld December 10, 4:18
DARMSTADT, Germany, July 18, 2016 /PRNewswire/. Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of the investigational product Cladribine Tablets for the treatment of relapsing-remitting multiple sclerosis (MS).
(Logo: http://photos.prnewswire.com/prnh/20160524/371574LOGO )
(Logo: http://photos.prnewswire.com/prnh/20151019/278051LOGO )
"Our submission of the Marketing Authorization Application for Cladribine Tablets demonstrates Merck's continued commitment to fighting the devastating disease of multiple sclerosis," said Luciano Rossetti, Head of Global R&D for the Biopharma business of Merck. "Although there are multiple therapies available for relapsing-remitting MS, there is still a significant unmet medical need with a focus on efficacy, dosing, durability and safety. We believe that Cladribine Tablets, if approved, would have a first-of-its-kind dosing regimen and serve as an important therapeutic option for patients with relapsing-remitting MS."
The MAA submission includes data from three Phase III studies, CLARITY, CLARITY EXTENSION and ORACLE MS, and the Phase II ONWARD study. In these trials, Cladribine Tablets showed significantly reduced relapse rates, risk of disability progression and development of new MS lesions, as detected by MRI, versus placebo in patients with relapsing-remitting MS.,,,, Together with interim long-term follow-up data from the prospective registry, PREMIERE, the new MAA also includes follow-up consisting of over 10,000 patient years of exposure in total, with follow-up in some patients exceeding eight years.
1) A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple
Sclerosis. New England Journal of Medicine.
http://www.nejm.org/doi/full/10.1056/NEJMoa0902533 Accessed May 5, 2016.
2) Safety and Efficacy of Oral Cladribine in Patients with Relapsing-Remitting Multiple
Sclerosis: Results from the 96 Week Phase IIIb Extension Trial to the CLARITY Study
(P07.119). Neurology. http://www.neurology.org/content/80/7_Supplement/P07.119.short?sid=f809adbd-a031-410b-97ad-fe26ccbee454
Accessed May 5, 2016.
3) Effect of Oral Cladribine on Time to Conversion to Clinically Definite Multiple
Sclerosis in Patients with a First Demyelinating Event (ORACLE MS): A Phase 3
Randomised Trial. Lancet
Neurology. http://www.ncbi.nlm.nih.gov/pubmed/24502830 Accessed May 5, 2016.
4) A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple
Sclerosis (MS) Subjects With Active Disease (ONWARD). Clinical
Accessed May 5, 2016.
5) Efficacy of Cladribine Tablets as Add-On to IFN-beta Therapy in Patients with Active
Relapsing MS: Final Results from the Phase II ONWARD Study. American Academy of
Neurology 2016 Meeting
Abstracts. http://www.abstractsonline.com/pp8/#!/4046/presentation/9728 Accessed
May 10, 2016.
6) Current and Emerging Therapies for the Treatment of Multiple Sclerosis: Focus on
Cladribine. Journal of Central Nervous System Disease.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619698 Accessed June 14, 2016.
About Cladribine Tablets
Cladribine Tablets is an oral small molecule prodrug that selectively and periodically targets lymphocytes thought to be integral to the pathological process of MS. Cladribine Tablets is currently under clinical investigation and not approved for any use in the United States, Canada and Europe.
About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.3 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of EUR 12.85 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Photo: http://photos.prnewswire.com/prnh/20160524/371574LOGO http://photos.prnewswire.com/prnh/20151019/278051LOGO Source: Merck
Gangolf Schrimpf, +49-6151-72-9591, Investor Relations, +49-6151-72-3321